Mesoblast Limited (ASX:MSB)
Australia · Delayed Price · Currency is AUD | Market Cap | 2.68B -9.9% |
| Revenue (ttm) | 173.82M +599.2% |
| Net Income | -83.12M |
| EPS | -0.06 |
| Shares Out | 1.30B |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,792,186 |
| Open | 2.040 |
| Previous Close | 2.040 |
| Day's Range | 2.030 - 2.085 |
| 52-Week Range | 1.880 - 3.310 |
| Beta | 0.82 |
| Analysts | Strong Buy |
| Price Target | 3.64 (+76.7%) |
| Earnings Date | Aug 26, 2026 |
About Mesoblast
Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia. The company’s proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers remestemcel-L-rknd, which is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, Duchenne muscular dystrophy, and biologic refractory inflammatory bowel disease, as well as ulcerative coli... [Read more]
Financial Performance
In fiscal year 2026, Mesoblast's revenue was $120.25 million, an increase of 599.21% compared to the previous year's $17.20 million. Losses were -$57.50 million, -43.71% less than in 2025.
Financial numbers in USD Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for MSB stock is "Strong Buy." The 12-month stock price target is $3.64, which is an increase of 76.70% from the latest price.
News
Mesoblast price target raised to $39 from $35 at Piper Sandler
Piper Sandler raised the firm’s price target on Mesoblast (MESO) to $39 from $35 and keeps an Overweight rating on the shares. Net Ryoncil revenues were $115M in FY26, and…
Full Year 2026 Mesoblast Limited Earnings Presentation Transcript
Full Year 2026 Mesoblast Limited Earnings Presentation Transcript
Mesoblast Reports Substantial Revenue Growth to US$120M
RYONCIL Market Share Expands; Phase 3 Back Pain Trial Completes Treatment Financial Results and Operational Update for Full Year Ended June 30, 2026 NEW YORK, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Mesobla...
Mesoblast H2 Earnings Call Highlights
Mesoblast NASDAQ: MESO reported $115 million in net revenue for fiscal 2026, its first full year of commercial sales for RYONCIL, the company's FDA-approved allogeneic mesenchymal stromal cell therapy...
Mesoblast Earnings Call Transcript: H2 2026
FY 2026 saw $115M net revenue and a 44% reduction in net loss, driven by RYONCIL's successful launch and broad adoption. Major phase III trials in adult GVHD, chronic low back pain, and heart failure are progressing, with double-digit revenue growth expected next year.
Mesoblast Annual report: H2 2026
Mesoblast has published its H2 2026 annual report on August 26, 2026.
Mesoblast Slides: H2 2026
Mesoblast has posted slides in relation to its H2 2026 quarterly earnings report, which was published on August 26, 2026.
Mesoblast Earnings release: H2 2026
Mesoblast released its H2 2026 earnings on August 26, 2026, summarizing the period's financial results.
Mesoblast Shares Jump 8.82% on ASX as Biotech Rebounds From Friday's Sharp Selloff Tied to State Street Filing
Mesoblast shares surged 8.82% on the ASX after a volatile week, recovering losses from a securities filing that unsettled investors. The company's revenue growth and clinical progress remain key focus...
Mesoblast completes patient treatment in MSB-DR004 in Phase 3 trial
Mesoblast (MESO) announced that it has completed patient treatment in the MSB-DR004 pivotal randomized controlled Phase 3 trial of rexlemestrocel-L for chronic low back pain, CLBP, associated with the...
Mesoblast Achieves Major Milestone Completing Patient Treatment in Pivotal Phase 3 Trial for Chronic Low Back Pain
NEW YORK, Aug. 16, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has completed pa...
Mesoblast Reports Ryoncil® Net Revenues of US$36M for the Quarter and US$115M for First Full Year of Product Launch
Expanding indications for RYONCIL in children and adults with life-threatening inflammatory diseases Achieved target of at least 300 Patients treated in Pivotal Phase 3 trial for Chronic Low Back Pain...
Mesoblast Achieves Target of 300 Treated Patients in Pivotal Phase 3 Trial for Chronic Low Back Pain
NEW YORK, July 13, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has achieved its...
Mesoblast reported Q4 Ryoncil net revenue of $36M
Last late week, Mesoblast (MESO) announced Ryoncil net revenue of $36M for the quarter and $115M for the full year ended June 30, 2026. “We are very pleased with the…
Ryoncil® Delivers Net Revenue of US$36M for the Fourth Quarter Ended 30 June 2026
NEW YORK, July 09, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced Ryoncil® (remestemcel-L-...
Mesoblast Earnings release: Q4 2026
Mesoblast released its Q4 2026 earnings on July 9, 2026, summarizing the period's financial results.
Mesoblast receives BLA filing number from FDA for rexlemestrocel-L review
Mesoblast (MESO) announced that it has received a Biologics License Application filing number from the U.S. Food and Drug Administration and has requested a modular review of its BLA for…
Mesoblast Receives BLA Filing Number and Requests Modular Review for Rexlemestrocel-L in Patients with End-Stage Heart Failure and LVADs
NEW YORK, June 30, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has received a B...
Mesoblast Draws US$50 Million from Five-Year Non-Dilutive Facility
Optimized capital structure, retiring short-term maturing debt Well-funded for commercial operations and growth pipeline NEW YORK, June 24, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX...
Mesoblast Slides: Investor presentation
Mesoblast has posted slides in relation to its latest quarterly earnings report, which was published on June 1, 2026.
Mesoblast Reports Ryoncil® Net Revenues of US$30.3m and Improved Net Operating Cash Spend for the Quarter to US$4.1 Million
Achieved Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain Activity Report for Quarter Ended March 31, 2026 (Appendix 4C) NEW YORK, April 29, 2026 (GLOBE NEWSWIRE) -- Mesob...
Mesoblast Earnings release: Q3 2026
Mesoblast released its Q3 2026 earnings on April 29, 2026, summarizing the period's financial results.
Mesoblast Achieves Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain
NEW YORK, April 28, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that its pivotal Phase ...
Mesoblast acquires chimeric antigen receptor platform technology
Mesoblast (MESO) “announced that it has acquired an exclusive worldwide license to a patented chimeric antigen receptor – CAR – technology platform for precision-enhanced augmentation of therapeutic m...